Project cooperationUpdated on 21 January 2026
Vaccine Improvement - Intradermally
President at NanoPass Technologies
Nes Ziona, Israel
About
NanoPass has developed the world's smallest vaccine injection device, and registered it in Europe, USA and most major markets. We have supported and conducted >70 clinical trials showing improved immunogenicity, durability, dose sparing and improved systemic AE's across all vaccine platforms (subunit, vv, mRNA, saRNA, DNA, inactivated and attenuated vaccines). We have previously partnered in EU consortia for same and seek partners to support vaccine development, particularly for pandemics. Promising Phase 1-2 results exist for pandemic flu, COVID and many other vaccines.
Similar opportunities
Project cooperation
- Consortium/Coordinator seeks Partners
- Partner seeks Consortium/Coordinator
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential
Daniela Ogonczyk-Makowska
R&D Project Leader at Vaxinano
Loos, France
Project cooperation
Alex Olvera van der Stoep
Research Associate at IrsiCaixa
Badalona, Spain
Project cooperation
Development of a vaccine against Tick-borne encephalitis virus
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential
Benjamin DAMIEN
CEO at SAGITTA BIOTECH
Liège, Belgium